*December 2019*
Checkpoint inhibitors come with a huge caveat: They only help a small subset of patients. Doctors struggle to predict who these patients are and—just as important—who they aren’t.
Results from a new study published Dec. 19 in the journal JCI Insight could help improve those forecasts.
